QIAGEN has Licensed a Novel Algorithm Developed by Novartis for the Selection of siRNA Sequences for Gene Silencing Applications
QIAGEN N.V. announced that it has licensed from Novartis Pharma AG a novel algorithm for the selection of highly functional target sequences for RNA interference applications. More than 3000 randomly designed synthetic siRNA duplexes, against 34 targets were analyzed for functionality. Based on this large data set, an automated siRNA sequence selection algorithm was developed. Extensive evaluation of the new algorithm has demonstrated a significant performance improvement over existing design methods.
Under the terms of this collaboration QIAGEN obtained a fully paid-up license from Novartis for the worldwide use of this prediction algorithm. Financial terms were not disclosed.
"We are very happy that Novartis has made this new resource available to QIAGEN", said Patrick A. Weiss, QIAGEN's Vice President of Gene Silencing and co-inventor of the TOM RNA chemistry. "This powerful tool complements QIAGEN's state of the art synthesis technology, combining biological functionality with high quality siRNA. This means that researchers can focus on their experiments and not on developing functional gene targeting reagents."
Organizations
Other news from the department business & finance
These products might interest you

Micro-Dx™ CE IVD by Molzym
Fully automated from sample to PCR analysis
Rapid identification of bacteria and fungi without time-consuming cultivation

DNA-free Taq Polymerases and Mastermixes by Molzym
DNA-free reagents for unrivalled sensitivity in molecular biology
Purity that makes the difference

CellGenix® Growth Factors and Cytokines by Sartorius
Recombinant growth factors without animal products
Optimised cell culture for T cells and MSCs in gene therapy

Recombumin® Elite by Sartorius
ICHQ7 cGMP-compliant albumin for biotechnological applications
Increase consistency and safety for gene therapies and vaccines

DNA/RNA Shield™ SafeCollect Collection Kits by Zymo Research
Sample collection devices for simple & safe at-home testing
Best user experience for secure self-collection

Greener Alternative Products by Merck Life Science
Sustainable laboratory products for environmentally conscious research
Over 2,500 ecological alternatives to reduce your laboratory footprint

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.